ImmunoPrecise Antibodies Ltd. (IPA)
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally.
It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign.
In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection.
The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel.
Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes.
Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain.
It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts.
The company was incorporated in 1983 and is headquartered in Victoria, Canada.
|IPO Date||Jan 3, 2017|
|CEO||Dr. Jennifer Lynne Bath Ph.D.|
880 - 580 Hornby Street
Vancouver, A1 V6C3B6
British Columbia, Canada
|Fiscal Year||May - April|
|Dr. Jennifer Lynne Bath Ph.D.||Chief Executive Officer, President and Non-Independent Director|
|Brad McConn||Chief Financial Officer|
|Dr. Ilse Roodink||Chief Scientific Officer|
|David E. Orton||Chief Operating Officer|
|Carla Dahl||Vice President of Marketing|
|Dr. Barry Neil Duplantis||Vice President of Client Relations|
Latest SEC Filings
|Nov 27, 2023||6-K||Report of foreign issuer|
|Nov 16, 2023||6-K||Report of foreign issuer|
|Nov 13, 2023||6-K||Report of foreign issuer|
|Oct 25, 2023||6-K||Report of foreign issuer|
|Oct 23, 2023||6-K||Report of foreign issuer|
|Oct 20, 2023||6-K||Report of foreign issuer|
|Sep 26, 2023||6-K||Report of foreign issuer|
|Sep 25, 2023||6-K||Report of foreign issuer|
|Sep 19, 2023||6-K||Report of foreign issuer|
|Sep 18, 2023||6-K||Report of foreign issuer|